Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems01:22

Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

8
Body:Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug...
8
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

191
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
191

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Shaping cell therapy manufacturing with metabolic understanding and control.

Trends in biotechnology·2026
Same author

Ferritin nanoparticles displaying rift valley fever virus glycoprotein elicit potent dendritic cell activation in vitro.

Virology journal·2026
Same author

MS-based workflow for PTM profiling of rAAV capsid proteins to support bioprocess monitoring and development.

Journal of biotechnology·2026
Same author

Bridging process diversity in cell therapies toward standardization of manufacturing workflows.

Cytotherapy·2026
Same author

Development of a serum-free producer cell line generation process for scalable and efficient rAAV production for gene therapy applications.

Journal of biotechnology·2026
Same author

Evaluation of gene editing in CHO cells using the Cas-CLOVER system.

Biotechnology progress·2026

Related Experiment Video

Updated: Oct 7, 2025

Multimodal Analytical Platform on a Multiplexed Surface Plasmon Resonance Imaging Chip for the Analysis of Extracellular Vesicle Subsets
06:12

Multimodal Analytical Platform on a Multiplexed Surface Plasmon Resonance Imaging Chip for the Analysis of Extracellular Vesicle Subsets

Published on: March 17, 2023

1.7K

Leveraging rAAV bioprocess understanding and next generation bioanalytics development.

Jose M Escandell1, Daniel Am Pais1, Sofia B Carvalho1

  • 1iBET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, Oeiras, 2780-901, Portugal; ITQB-NOVA, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Av. Da República, Oeiras, 2780-157, Portugal.

Current Opinion in Biotechnology
|January 10, 2022
PubMed
Summary

Recombinant adeno-associated (rAAV) vector gene therapy shows promise, but scaling up production faces challenges. Addressing R&D and manufacturing (CMC) needs is crucial for meeting the growing demand for these advanced therapies.

More Related Videos

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.0K
Author Spotlight: A Cost-Effective Genomic Workflow for Advancing Rabies Control in Resource-Limited Settings
10:26

Author Spotlight: A Cost-Effective Genomic Workflow for Advancing Rabies Control in Resource-Limited Settings

Published on: August 18, 2023

5.9K

Related Experiment Videos

Last Updated: Oct 7, 2025

Multimodal Analytical Platform on a Multiplexed Surface Plasmon Resonance Imaging Chip for the Analysis of Extracellular Vesicle Subsets
06:12

Multimodal Analytical Platform on a Multiplexed Surface Plasmon Resonance Imaging Chip for the Analysis of Extracellular Vesicle Subsets

Published on: March 17, 2023

1.7K
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.0K
Author Spotlight: A Cost-Effective Genomic Workflow for Advancing Rabies Control in Resource-Limited Settings
10:26

Author Spotlight: A Cost-Effective Genomic Workflow for Advancing Rabies Control in Resource-Limited Settings

Published on: August 18, 2023

5.9K

Area of Science:

  • Biotechnology
  • Gene Therapy
  • Viral Vector Development

Background:

  • Recombinant adeno-associated (rAAV) vectors are central to gene therapy research due to their safety and recent clinical successes.
  • Two rAAV-based gene therapies are approved, with over 200 clinical trials underway, indicating significant therapeutic potential.

Purpose of the Study:

  • To discuss the research and development (R&D) needs and Chemistry, Manufacturing, and Control (CMC) strategies for scaling up rAAV vector production.
  • To identify key factors for the successful clinical translation and commercialization of rAAV-based gene therapies.

Main Methods:

  • Review of current landscape of rAAV-based gene therapies and clinical trials.
  • Analysis of challenges in R&D and CMC for large-scale rAAV vector manufacturing.
  • Discussion of strategic approaches for enhancing scalability, safety, and process understanding.

Main Results:

  • Significant increase in demand for rAAV vectors presents manufacturing and logistical challenges.
  • Key areas for advancement include improving scalability, productivity, and safety of rAAV production.
  • Enhanced process understanding and development of orthogonal bioanalytical methods are critical for controlling Critical Quality Attributes (CQAs).

Conclusions:

  • Strategic focus on scalable manufacturing, process understanding, and robust analytics is essential for the widespread adoption of rAAV gene therapies.
  • Addressing CMC challenges proactively will facilitate the delivery of novel gene therapies to patients.
  • Continued innovation in bioprocessing and bioanalytics will support the growing pipeline of rAAV-based treatments.